Lupin is planning to make significant investments in Japan, the second biggest pharmaceutical market in the world. The company is setting up a new plant in Japan and investing Rs 100 crore in a manufacturing facility in India which will cater to the Japanese market.
Lupin, which entered Japan through acquisitions, reported 9% year-on-year growth in its business in the country in the third quarter of financial year 2016.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.
